10023-07-1

Basic information

• Product Name: [(1R,3S,4aS,10aR)-9-hydroxy-5,10-dioxo-1-propyl-3,4,5,10-tetrahydro-4a,10a-epoxybenzo[g]isochromen-3(1H)-yl]acetic acid
• Synonyms: [1R-(1a,3b,4ab,10ab)]-3,4,5,10-Tetrahydro-9-hydroxy-5,10-dioxo-1-propyl-4a,10a-epoxy-1H-naphtho[2,3-c]pyran-3-acetic Acid; 10023-07-1
• CAS NO: 10023-07-1
• Molecular Formula: C₁₈H₁₈O₇
• Molecular Weight: 346.3313
• Mol File: 10023-07-1.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 655.774°C at 760 mmHg
• Flash Point: 243.284°C
• Density: 1.51g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.644
• CAS DataBase Reference: [(1R,3S,4aS,10aR)-9-hydroxy-5,10-dioxo-1-propyl-3,4,5,10-tetrahydro-4a,10a-epoxybenzo[g]isochromen-3(1H)-yl]acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: [(1R,3S,4aS,10aR)-9-hydroxy-5,10-dioxo-1-propyl-3,4,5,10-tetrahydro-4a,10a-epoxybenzo[g]isochromen-3(1H)-yl]acetic acid(10023-07-1)
• EPA Substance Registry System: [(1R,3S,4aS,10aR)-9-hydroxy-5,10-dioxo-1-propyl-3,4,5,10-tetrahydro-4a,10a-epoxybenzo[g]isochromen-3(1H)-yl]acetic acid(10023-07-1)

Safety Data

• Hazardous Substances Data: 10023-07-1(Hazardous Substances Data)

Usage

General Description

The chemical compound [(1R,3S,4aS,10aR)-9-hydroxy-5,10-dioxo-1-propyl-3,4,5,10-tetrahydro-4a,10a-epoxybenzo[g]isochromen-3(1H)-yl]acetic acid is a complex organic molecule with a unique structure. It contains a hydroxy group, a propyl group, and an epoxybenzo[g]isochromen-3(1H)-yl group, as well as a carboxylic acid functional group. The compound has potential pharmaceutical and medicinal properties due to its complex structure, which may allow it to interact with biological systems in unique ways. Further research into this compound's properties and potential applications may be of interest to the scientific community.

Upstream product

• 10023-09-3 (+/-)-frenolicin methyl ester 
• 1450893-33-0 frenolicin F 
• 73804-48-5 trans-methyl <9-hydroxy-1-propyl-5,10-dioxo-3,4,5,10-tetrahydro-1H-naphtho<2,3-c>pyran-3-yl>acetate 
• 77363-69-0 (E)-4-[(3aR,4S,5S,6S)-6-Hydroxy-4-((S)-1-hydroxy-butyl)-2,2-dimethyl-3a,4,5,6-tetrahydro-naphtho[1,8-de][1,3]dioxin-5-yl]-but-2-enoic acid methyl ester 
• 73794-57-7 ((7R,7aR,9S,11R,11aR,11bS)-7-Hydroxy-2,2-dimethyl-11-propyl-7,8,9,11,11a,11b-hexahydro-7aH-1,3,10-trioxa-benzo[de]anthracen-9-yl)-acetic acid methyl ester 
• 73794-58-8 ((7aS,9R,11S,11aS,11bR)-2,2-Dimethyl-7-oxo-11-propyl-7,8,9,11,11a,11b-hexahydro-7aH-1,3,10-trioxa-benzo[de]anthracen-9-yl)-acetic acid methyl ester 
• 73794-56-6 (7S,7aS,9R,11S,11aS,11bR)-2,2-Dimethyl-11-propyl-7,8,9,11,11a,11b-hexahydro-7aH-1,3,10-trioxa-benzo[de]anthracene-7,9-diol 
• 73804-49-6 (+/-)-deoxyfrenolicin 

Downstream Products

• 10023-11-7 Deoxyfrenolicin 

Relevant articles and documents

Frenolicins C-G, Pyranonaphthoquinones from streptomyces sp. RM-4-15

Appalachian active coal fire sites were selected for the isolation of bacterial strains belonging to the class actinobacteria. A comparison of high-resolution electrospray ionization mass spectrometry (HRESIMS) and ultraviolet (UV) absorption profiles from isolate extracts to natural product databases suggested Streptomyces sp. RM-4-15 to produce unique metabolites. Four new pyranonaphthoquinones, frenolicins C-F (1-4), along with three known analogues, frenolicin (6), frenolicin B (7), and UCF76-A (8), were isolated from the fermentation of this strain. An additional new analogue, frenolicin G (5), along with two known compounds, deoxyfrenolicin (9) and UCF 13 (10), were isolated from the fermentation supplied with 18 mg/L of scandium chloride, the first example, to the best of our knowledge, wherein scandium chloride supplementation led to the confirmed production of new bacterial secondary metabolites. Structures 1-5 were elucidated on the basis of spectral analysis and chemical modification. While frenolicins are best known for their anticoccidial activity, the current study revealed compounds 6-9 to exhibit moderate cytotoxicity against the human lung carcinoma cell line (A549) and thereby extends the anticancer SAR for this privileged scaffold.